Biomarkers in the management of pneumonia

References

• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med.336(4), 243–250 (1997).
   PubMed Web of Science ®Google Scholar
• Lim WS, Macfarlane JT, Boswell TC et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax56(4), 296–301 (2001).
   PubMed Web of Science ®Google Scholar
• Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax58(5), 377–382 (2003).
   PubMed Web of Science ®Google Scholar
• Hoare Z, Lim WS. Pneumonia: update on diagnosis and management. BMJ332(7549), 1077–1079 (2006).
   PubMedGoogle Scholar
• Hopstaken RM, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br. J. Gen. Pract.53(490), 358–364 (2003).
   PubMed Web of Science ®Google Scholar
• Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect. Dis.4(2), 112–124 (2004).
   PubMed Web of Science ®Google Scholar
• Goossens H, Little P. Community acquired pneumonia in primary care. BMJ332(7549), 1045–1046 (2006).
   PubMedGoogle Scholar
• O’Donnell WJ, Kradin RL, Evins AE, Wittram C. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-2004. A 52-year-old woman with recurrent episodes of atypical pneumonia. N. Engl. J. Med.351(26), 2741–2749 (2004).
   PubMed Web of Science ®Google Scholar
• Genne D, Kaiser L, Kinge TN, Lew D. Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin. Microbiol. Infect.9(9), 949–954 (2003).
   PubMed Web of Science ®Google Scholar
• Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA278(23), 2080–2084 (1997).
   PubMed Web of Science ®Google Scholar
• Muller B, Harbarth S, Stolz D et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect. Dis.7(1), 10 (2007).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Mandell LA. What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Clin. Infect. Dis.36(4), 396–398 (2003).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis.37(11), 1405–1433 (2003).
   PubMed Web of Science ®Google Scholar
• File TM Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin. Infect. Dis.39(Suppl. 3), S159–S164 (2004).
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med.163(7), 1730–1754 (2001).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Menendez R, Torres A, Zalacain R et al. Guidelines for the treatment of community-acquired pneumonia, predictors of adherence and outcome. Am. J. Respir. Crit. Care Med.172(6), 757–762 (2005).
   PubMed Web of Science ®Google Scholar
• Aujesky D, Fine MJ. Does guideline adherence for empiric antibiotic therapy reduce mortality in community-acquired pneumonia? Am. J. Respir. Crit. Care Med.172(6), 655–656 (2005).
   PubMed Web of Science ®Google Scholar
• Mandell LA, File TM Jr. Short-course treatment of community-acquired pneumonia. Clin. Infect. Dis.37(6), 761–763 (2003).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet363(9409), 600–607 (2004).
   PubMed Web of Science ®Google Scholar
• Wipf JE, Lipsky BA, Hirschmann JV et al. Diagnosing pneumonia by physical examination: relevant or relic? Arch. Intern. Med.159(10), 1082–1087 (1999).
   PubMed Web of Science ®Google Scholar
• Muller B. Procalcitonin and ventilator-associated pneumonia: yet another breath of fresh air. Am. J. Respir. Crit. Care Med.171(1), 2–3 (2005).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Muller B. Procalcitonin in bacterial infections – hype, hope, more or less? Swiss Med. Wkly135(31–32), 451–460 (2005).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med.174(1), 84–93 (2006).
   PubMed Web of Science ®Google Scholar
• Hug B, Rossi M. A year’s review of bacterial pneumonia at the central hospital of Lucerne, Switzerland. Swiss Med. Wkly131(47–48), 687–692 (2001).
   PubMed Web of Science ®Google Scholar
• Carratala J, Fernandez-Sabe N, Ortega L et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann. Intern. Med.142(3), 165–172 (2005).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin–clavulanate (2,000/125 milligrams) versus those of amoxicillin–clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob. Agents Chemother.48(9), 3323–3331 (2004).
   PubMed Web of Science ®Google Scholar
• Musher DM, Alexandraki I, Graviss EA et al. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore)79(4), 210–221 (2000).
   PubMed Web of Science ®Google Scholar
• Tan MJ, Tan JS, Hamor RH, File TM Jr, Breiman RF. The radiologic manifestations of Legionnaire’s disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest117(2), 398–403 (2000).
   PubMed Web of Science ®Google Scholar
• Arancibia F, Bauer TT, Ewig S et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch. Intern. Med.162(16), 1849–1858 (2002).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Wolbers M et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv. Res.7, 102 (2007).
   PubMed Web of Science ®Google Scholar
• Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am. J. Respir. Crit. Care Med.177(5), 498–505 (2008).
   PubMed Web of Science ®Google Scholar
• Moulin F, Raymond J, Lorrot M et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch. Dis. Child.84(4), 332–336 (2001).
   PubMed Web of Science ®Google Scholar
• Chastre J, Fagon JY. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med.165(7), 867–903 (2002).
   PubMed Web of Science ®Google Scholar
• Duflo F, Debon R, Monneret G, Bienvenu J, Chassard D, Allaouchiche B. Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology96(1), 74–79 (2002).
   PubMed Web of Science ®Google Scholar
• Oppert M, Reinicke A, Muller C, Barckow D, Frei U, Eckardt KU. Elevations in procalcitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation53(2), 167–170 (2002).
   PubMed Web of Science ®Google Scholar
• Gibot S, Cravoisy A. Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin. Med. Res.2(3), 181–187 (2004).
   PubMedGoogle Scholar
• Luyt CE, Guerin V, Combes A et al.Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med.171(1), 48–53 (2005).
   PubMed Web of Science ®Google Scholar
• Gibot S, Cravoisy A, Kolopp-Sarda MN et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit. Care Med.33(4), 792–796 (2005).
   PubMed Web of Science ®Google Scholar
• Horonenko G, Hoyt JC, Robbins RA et al. Soluble triggering receptor expressed on myeloid cell-1 is increased in patients with ventilator-associated pneumonia: a preliminary report. Chest132(1), 58–63 (2007).
   PubMed Web of Science ®Google Scholar
• Mueller B, Gencay MM, Gibot S et al. Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM-1) in community-acquired pneumonia. Crit. Care Med.35(3), 990–991 (2007).
   PubMed Web of Science ®Google Scholar
• Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N. Engl. J. Med.350(5), 451–458 (2004).
   PubMed Web of Science ®Google Scholar
• Muller B, Tamm M. Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king. Am. J. Respir. Crit. Care Med.174(8), 848–849 (2006).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med.171(4), 388–416 (2005).
   PubMed Web of Science ®Google Scholar
• Almirall J, Bolibar I, Toran P et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest125(4), 1335–1342 (2004).
   PubMed Web of Science ®Google Scholar
• Masia M, Gutierrez F, Shum C et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest128(4), 2223–2229 (2005).
   PubMed Web of Science ®Google Scholar
• Querol-Ribelles JM, Tenias JM, Grau E et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest126(4), 1087–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit. Care Med.34(10), 2596–2602 (2006).
   PubMed Web of Science ®Google Scholar
• Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intens. Care Med.32(3), 469–472 (2006).
   PubMed Web of Science ®Google Scholar
• Seligman R, Meisner M, Lisboa TC et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit. Care10(5), R125 (2006).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Morgenthaler NG, Stolz D et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit. Care10(3), R96 (2006).
   PubMed Web of Science ®Google Scholar
• Muller B, Suess E, Schuetz P et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J. Intern. Med.260(6), 568–576 (2006).
   PubMed Web of Science ®Google Scholar
• Muller B, Morgenthaler N, Stolz D et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur. J. Clin. Invest.37(2), 145–152 (2007).
   PubMed Web of Science ®Google Scholar
• Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr. Rev.21(2), 138–167 (2000).
   PubMed Web of Science ®Google Scholar
• Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides22(11), 1693–1711 (2001).
   PubMed Web of Science ®Google Scholar
• Kitamura K, Kangawa K, Kawamoto M et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun.192(2), 553–560 (1993).
   PubMed Web of Science ®Google Scholar
• Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology146(6), 2699–2708 (2005).
   PubMed Web of Science ®Google Scholar
• Hirata Y, Mitaka C, Sato K et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J. Clin. Endocrinol. Metab.81(4), 1449–1453 (1996).
   PubMed Web of Science ®Google Scholar
• Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides25(8), 1369–1372 (2004).
   PubMed Web of Science ®Google Scholar
• Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Muller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit. Care9(1), R37–R45 (2005).
   Google Scholar
• Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin. Chem.50(1), 234–236 (2004).
   PubMed Web of Science ®Google Scholar
• Aiura K, Ueda M, Endo M, Kitajima M. Circulating concentrations and physiologic role of atrial natriuretic peptide during endotoxic shock in the rat. Crit. Care Med.23(11), 1898–1906 (1995).
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet351(9095), 9–13 (1998).
   PubMed Web of Science ®Google Scholar
• Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr. Rev.24(3), 341–356 (2003).
   PubMed Web of Science ®Google Scholar
• Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet350(9088), 1349–1353 (1997).
   PubMed Web of Science ®Google Scholar
• Masia M, Papassotiriou J, Morgenthaler NG, Hernandez I, Shum C, Gutierrez F. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin. Chem.53(12), 2193–2201 (2007).
   PubMed Web of Science ®Google Scholar
• Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J. Intern. Med.258(4), 391–393 (2005).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Breidthardt T, Stolz D et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J. Intern. Med.264(2), 166–176 (2008).
   PubMed Web of Science ®Google Scholar
• Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin. Chem.52(6), 1144–1151 (2006).
   PubMed Web of Science ®Google Scholar
• Hemsen A, Modin A, Weitzberg E. Increased concentrations of endothelin-1 messenger RNA in tissues and endothelin-1 peptide in plasma in septic pigs: modulation by betamethasone. Crit. Care Med.24(9), 1530–1536 (1996).
   PubMed Web of Science ®Google Scholar
• Brauner JS, Rohde LE, Clausell N. Circulating endothelin-1 and tumor necrosis factor-α: early predictors of mortality in patients with septic shock. Intens. Care Med.26(3), 305–313 (2000).
   PubMed Web of Science ®Google Scholar
• Tschaikowsky K, Sagner S, Lehnert N, Kaul M, Ritter J. Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit. Care Med.28(6), 1854–1860 (2000).
   PubMed Web of Science ®Google Scholar
• Wanecek M, Oldner A, Sundin P, Alving K, Weitzberg E, Rudehill A. Effects on haemodynamics by selective endothelin ET(B) receptor and combined endothelin ET(A)/ET(B) receptor antagonism during endotoxin shock. Eur. J. Pharmacol.386(2–3), 235–245 (1999).
   PubMed Web of Science ®Google Scholar
• Krejci V, Hiltebrand LB, Erni D, Sigurdsson GH. Endothelin receptor antagonist bosentan improves microcirculatory blood flow in splanchnic organs in septic shock. Crit. Care Med.31(1), 203–210 (2003).
   PubMed Web of Science ®Google Scholar
• Oldner A, Wanecek M, Goiny M et al. The endothelin receptor antagonist bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock. Gut42(5), 696–702 (1998).
   PubMed Web of Science ®Google Scholar
• Iskit AB, Senel I, Sokmensuer C, Guc MO. Endothelin receptor antagonist bosentan improves survival in a murine caecal ligation and puncture model of septic shock. Eur. J. Pharmacol.506(1), 83–88 (2004).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Stolz D, Mueller B et al. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect. Dis.8(1), 22 (2008).
   PubMedGoogle Scholar
• Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin (AVP) precursor, is elevated in hemorrhagic and septic shock. Shock28(2), 219–226 (2007).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Stolz D, Jutla S et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am. J. Respir. Crit. Care Med.176(9), 913–920 (2007).
   PubMed Web of Science ®Google Scholar
• dcMenendez R, Cavalcanti M, Reyes S et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax63(5), 447–452 (2008).
   PubMed Web of Science ®Google Scholar